Full-Time

Principal Electrical Engineer

Posted on 9/18/2024

Medtronic

Medtronic

10,001+ employees

Develops and manufactures medical devices and therapies

Compensation Overview

$125.6k - $188.4kAnnually

+ Short-term incentive (Medtronic Incentive Plan)

Senior

Minneapolis, MN, USA

Related to Core R&D group in Rice Creek, Minnesota.

Category
Electronics Design Engineering
Embedded Systems Engineering
Electrical Engineering
Requirements
  • Bachelor’s degree in a technical discipline
  • Minimum of 7 years of relevant experience, or advanced degree with a minimum of 5 years relevant experience
  • BS or MS in Electrical or Computer Engineering
  • MR safety experience for Medical Devices
  • Strong understanding of electromagnetics and their interactions with Medical Devices
  • Proven experience in computational M&S in the context of electromagnetics and Medical Devices
  • Proficiency in relevant multiphysics simulation tools such as Sim4Life, ANSYS, etc.
  • Experience with model verification and validation in accordance with V&V40 or other standards
  • Experience validating test scripts, methods and systems
  • Experience in hardware integration of RF subsystems
  • Experience designing analog and digital circuitry on custom PCBs
Responsibilities
  • Provide technical leadership on M&S based MR safety development and test for Implantable Medical Devices
  • Provide electrical and Radiofrequency (RF) engineering skills to design, develop, characterize, and verify MR safety in new product designs
  • Fundamental understanding of MR induced RF, gradient, and static fields, and associated MR safety design for Implantable Medical Devices
  • Work closely with other Engineers and Technicians to verify and validate multiphysics based Medical Device and lead heating models
  • Analysis of product performance using DFSS techniques
  • Design and execute test methods to characterize MR safety and verify adherence to standards, product, and systems requirements
  • Validate test environments comprising custom RF equipment, software, and test methods
  • Interface with certified test houses to verify/certify to global regulatory standards including ISO 14708-3, ISO/TS 10974, IEC 60601-2-33, etc.
  • Work under minimal supervision
  • Ensure understanding of all quality policy/system items that are personally applicable. Follow all work/quality procedures to ensure quality system compliance and high-quality work
  • Ability to work with others internationally and travel globally

Medtronic provides medical technology, services, and solutions to improve patient care. The company develops a variety of medical devices, such as pacemakers, insulin pumps, surgical tools, and neurostimulation devices, which help diagnose, prevent, and treat chronic diseases. These products are used by hospitals, clinics, and healthcare professionals around the world. Medtronic stands out from competitors by not only focusing on product development but also offering comprehensive services, including training for healthcare providers and patient management programs. The goal of Medtronic is to enhance patient outcomes and lower healthcare costs through its advanced medical solutions.

Company Size

10,001+

Company Stage

IPO

Total Funding

$3.2M

Headquarters

Fridley, Minnesota

Founded

1949

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of BrainSense™ DBS boosts Medtronic's neurology market leadership.
  • Evolut TAVR's superior performance may increase cardiovascular market sales.
  • Collaboration with Philips enhances Medtronic's presence in emerging markets.

What critics are saying

  • Increased TAVR market competition may impact Medtronic's market share.
  • Dividend increases could strain Medtronic's cash flow and R&D investment.
  • High cost of BrainSense™ DBS may hinder adoption and reimbursement.

What makes Medtronic unique

  • Medtronic's BrainSense™ Adaptive DBS system is a pioneering neurological treatment innovation.
  • The Evolut TAVR system shows superior valve performance in the SMART Trial.
  • Medtronic's 10-year initiative aims to train 1 million students in health tech careers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Company News

PR Newswire
Mar 9th, 2025
Smart Trial Two-Year Data Continues To Demonstrate Superior Valve Performance For Evolut Tavr™ System In Small Annulus Patients

CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial to primarily enroll women using the two most widely used global TAVR devicesGALWAY, Ireland and WASHINGTON, March 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR). In patients with aortic stenosis and a small aortic annulus, results showed comparable composite outcome of mortality, disabling stroke, and heart failure hospitalization, and continued superior valve performance as measured by bioprosthetic valve dysfunction (BVD) at two years for Evolut™ TAVR compared to SAPIEN™. The late-breaking science was presented at the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C."Valve performance is critical for all patients, but the impact of poor valve performance is magnified in patients with a small aortic annulus, who are at risk of receiving a valve that is not adequate for their cardiac requirements," said Howard C. Herrmann, M.D., Perelman School of Medicine at the University of Pennsylvania, and lead investigator of the trial. "The two-year results highlight the continued superior performance of the Evolut TAVR valve in these patients. While we would not yet expect to see a significant difference in the composite clinical outcomes at this early stage, valve performance provides important data that operators can use to inform and personalize treatment decisions to enhance patient outcomes."The SMART two-year data demonstrated that Evolut TAVR continues to show significantly less BVD, which can be a predictor of adverse outcomes1, compared to SAPIEN TAVR

PR Newswire
Mar 6th, 2025
Medtronic Announces Cash Dividend For Fourth Quarter Of Fiscal Year 2025

GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the SP 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions

PR Newswire
Mar 4th, 2025
Jumpstart Ventures Announces First Close For Next Fund Iii

CLEVELAND, Ohio, March 4, 2025 /PRNewswire/ -- JumpStart Ventures has achieved the successful first close of NEXT Fund III, raising nearly $25 million toward its $50 million target. NEXT Fund III is supported by the State Small Business Credit Initiative (SSBCI) Ohio, institutional and private investors and reinforces JumpStart Ventures' commitment to providing tech founders with the capital they need to scale their startups.NEXT Fund III will invest in Seed and Series A startups and build upon JumpStart Ventures' two decades of experience supporting high-growth startups with risk capital while generating top returns for their investment partners.NEXT Fund III is JumpStart Ventures' third fund under its NEXT model and its eighth venture capital fund overall. With this first close, JumpStart Ventures is positioned to continue its momentum of funding high-growth startups."This close represents a significant step forward in supporting our region's most ambitious founders," said Hardik Desai, Managing Partner of JumpStart Ventures. "With the backing of our committed partners, we are focused on providing the capital and resources needed to help founders scale their businesses and bring groundbreaking technologies to market."JumpStart Ventures' portfolio has brought much excitement to the region's venture capital ecosystem in recent years, as demonstrated by the growth of several venture-backed startups like Abre, Centerline Biomedical, OnStation, Cleveland Diagnostics, Orthobrain, Axuall and Onshift. 30+ portfolio companies like CoverMyMeds, Able Software, Wireless Environment, CardioInsight, and Vizzle have been acquired generating significant returns for the investors.JumpStart Ventures manages four unique investment funds to drive startup growth, pairing stage-appropriate capital with deep connections and partnerships. As one of Ohio's most active early-stage investors, the organization's investment activities have generated top quartile investment returns via nationally recognized exits and fundraises

CSRwire
Mar 4th, 2025
Medtronic Launches Bold 10-Year Global Initiative To Propel 1M Low-Income Students Into Health Tech Careers

Medtronic launches Bold 10-year global initiative to propel 1M low-income students into health tech careers.

Asian Hospital & Healthcare Management
Mar 1st, 2025
Philips and Medtronic to Train Over 300 Clinicians in Structural Heart Imaging in India

Philips, a global leader in health technology, has partnered with Medtronic, a leading medical technology company, to train cardiologists and radiologists in India on advanced imaging techniques for structural heart diseases.

INACTIVE